NDA 211109 · Tetraphase Pharms
Xerava
Eravacycline Dihydrochloride · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 27, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
298
227 serious, 50 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 4, 2026.
XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. ( 1.1 ) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Complicated Intra-abdominal Infections XERAVA is indicated for the treatment of complicated intra‑abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens , Bacteroides species, and Parabacteroides distasonis in patients 18 years or older [see Microbiology ( 12.4 ) and Clinical Studies ( 14.1 )]. Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies ( 14.2 )] . 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Eravacycline is an antibacterial drug [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 27, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
- XERAVA · ERAVACYCLINE DIHYDROCHLORIDE EQ 50MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
- XERAVA · ERAVACYCLINE DIHYDROCHLORIDE EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eravacycline Dihydrochloride" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use98
- drug ineffective33
- blood fibrinogen decreased29
- thrombocytopenia18
- nausea15
- product use in unapproved indication15
- diarrhoea14
- multiple organ dysfunction syndrome14
- condition aggravated12
- coagulopathy11
- hypofibrinogenaemia11
- lactic acidosis11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 12 |
| 2020 | 10 |
| 2021 | 15 |
| 2022 | 29 |
| 2023 | 52 |
| 2024 | 41 |
| 2025 | 45 |
| 2026 | 94 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xerava (Eravacycline Di-Hydrochloride)
2024 spending
$690K
Beneficiaries
167
844 claims
Per beneficiary
$4,133
$2.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $271,814 |
| 2021 | $402,034 |
| 2022 | $664,236 |
| 2023 | $788,061 |
| 2024 | $690,199 |
Part B: Xerava (Eravacycline Di-Hydrochloride) · HCPCS J0122
2024 spending
$146K
Beneficiaries
59
639 claims
Per beneficiary
$2,476
2024 ASP limit $1.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $117,915 |
| 2021 | $83,663 |
| 2022 | $176,423 |
| 2023 | $108,177 |
| 2024 | $146,105 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Tetraphase Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.